Tissue Diagnostics Market by Product (Consumables, Instruments), Technology (Immunohistochemistry, in Situ Hybridization, Digital Pathology and Workflow), Disease (Breast Cancer, Gastric Cancer, Lymphoma), End User (Hospital, CRO) - Global Forecast to 2024

1 Introduction
   1.1 Market Definition
   1.2 Market Ecosystem
   1.3 Years Considered in the Study
   1.4 Currency & Limitations
   1.5 Key Stakeholders

2 Research Methodology
   2.1 Secondary Research
   2.2 Primary Research
   2.3 Market Size Estimation

3 Executive Summary

4 Market Insights
   4.1 Drivers
         4.1.1 Inflation in Cancer Patients
         4.1.2 Improving Infrastructure for Cancer Diagnosis
         4.1.3 Increasing Healthcare Expenditure
         4.1.4 Technological Advancements in Tissue Diagnostics
   4.2 Restraints
         4.2.1 Regulatory Framework Issues
         4.2.2 Limited Budgets
   4.3 Opportunities
         4.3.1 Rising Adoption of Personalized Medicine
         4.3.2 Rising Number of Clinical Trials for Cancer Drugs
         4.3.3 Growing Opportunities in Digital Pathology
         4.3.4 Emerging Economies
   4.4 Challenges
         4.4.1 Shortage of Qualified Pathologists
         4.4.2 Reimbursement Cuts
   4.5 Trends
         4.5.1 Increasing Number of Reagent Rental Contracts

5 Global Tissue Diagnostics Market, by Product
   5.1 Introduction
   5.2 Consumables
         5.2.1 Antibodies
         5.2.2 Kits
         5.2.3 Reagents
         5.2.4 Probes
   5.3 Instruments
         5.3.1 Slide-Staining Systems
         5.3.2 Scanners
         5.3.3 Tissue-Processing Systems
         5.3.4 Other Instruments

6 Global Tissue Diagnostics Market, by Technology
   6.1 Introduction
   6.2 Immunohistochemistry (IHC)
   6.3 in Situ Hybridization (ISH)
   6.4 Digital Pathology and Workflow Management
   6.5 H&E Slide Staining
   6.6 Special Staining

7 Global Tissue Diagnostics Market, by Disease
   7.1 Introduction
   7.2 Breast Cancer
   7.3 Gastric Cancer
   7.4 Prostrate Cancer
   7.5 Lung Cancer
   7.6 Lymphoma
   7.7 Non-Small Cell Lung Cancer (NSCLC)
   7.8 Other Diseases

8 Global Tissue Diagnostics Market, by End User
   8.1 Introduction
   8.2 Hospitals
   8.3 Research Laboratories
   8.4 Pharmaceutical Companies
   8.5 Contract Research Organizations
   8.6 Ambulatory Surgical Centers
   8.7 Other End Users

9 Global Tissue Diagnostics Market, by Geography
   9.1 North America
         9.1.1 U.S.
         9.1.2 Canada
   9.2 Europe
         9.2.1 Germany
         9.2.2 France
         9.2.3 U.K.
         9.2.4 Italy
         9.2.5 Spain
         9.2.6 Rest of Europe
   9.3 Asia-Pacific
         9.3.1 Japan
         9.3.2 China
         9.3.3 India
         9.3.4 Rest of Asia-Pacific
   9.4 Rest of the World
         9.4.1 Latin America
         9.4.2 Middle East & Africa

10 Global Tissue Diagnostics Market - Competitive Landscape
     10.1 Introduction
     10.2 Competitive Benchmarking
     10.3 Tissue Diagnostics Market Share Analysis

11 Company Profiles
     11.1 F. Hoffmann-La Roche Ltd
            11.1.1 Business Overview
            11.1.2 Financial Overview
            11.1.3 Product Portfolio
            11.1.4 Strategic Developments
     11.2 Danaher Corporation
            11.2.1 Business Overview
            11.2.2 Financial Overview
            11.2.3 Product Portfolio
            11.2.4 Strategic Developments
     11.3 Thermo Fisher Scientific Inc.
            11.3.1 Business Overview
            11.3.2 Financial Overview
            11.3.3 Product Portfolio
            11.3.4 Strategic Developments
     11.4 Abbott Laboratories
            11.4.1 Business Overview
            11.4.2 Financial Overview
            11.4.3 Product Portfolio
            11.4.4 Strategic Developments
     11.5 Agilent Technologies, Inc.
            11.5.1 Business Overview
            11.5.2 Financial Overview
            11.5.3 Product Portfolio
            11.5.4 Strategic Developments
     11.6 Merck KGaA (Sigma-Aldrich Co. LLC)
            11.6.1 Business Overview
            11.6.2 Financial Overview
            11.6.3 Product Portfolio
            11.6.4 Strategic Developments
     11.7 Sakura Finetek Japan Co., Ltd.
            11.7.1 Business Overview
            11.7.2 Financial Overview
            11.7.3 Product Portfolio
            11.7.4 Strategic Developments
     11.8 Abcam plc.
            11.8.1 Business Overview
            11.8.2 Financial Overview
            11.8.3 Product Portfolio
            11.8.4 Strategic Developments
     11.9 Becton, Dickinson, and Company (BD)
            11.9.1 Business Overview
            11.9.2 Financial Overview
            11.9.3 Product Portfolio
            11.9.4 Strategic Developments
     11.10 QIAGEN
              11.10.1 Business Overview
              11.10.2 Financial Overview
              11.10.3 Product Portfolio
              11.10.4 Strategic Developments
     11.11 Bio SB
              11.11.1 Business Overview
              11.11.2 Financial Overview
              11.11.3 Product Portfolio
              11.11.4 Strategic Developments
     11.12 BioGenex
              11.12.1 Business Overview
              11.12.2 Financial Overview
              11.12.3 Product Portfolio
              11.12.4 Strategic Developments
     11.13 Cell Signaling Technology, Inc.
              11.13.1 Business Overview
              11.13.2 Financial Overview
              11.13.3 Product Portfolio
              11.13.4 Strategic Developments
     11.14 3DHISTECH Ltd.
              11.14.1 Business Overview
              11.14.2 Financial Overview
              11.14.3 Product Portfolio
              11.14.4 Strategic Developments
     11.15 Cancer Genetics Inc.
              11.15.1 Business Overview
              11.15.2 Financial Overview
              11.15.3 Product Portfolio
              11.15.4 Strategic Developments

12 Appendix 
     12.1 Questionnaire